[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592879":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":25,"overallOfficials":13,"centralContacts":31,"locations":41,"responsibleParty":61,"collaborators":13,"id":64,"slug":13,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":13,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":13,"enrollmentInfo":72,"targetDuration":13,"studyType":75,"phases":13,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":44,"whyStopped":13,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"University Hospital Muenster","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Correlation of multiparametric MRI parameters with early therapy response","Evaluation of mpMRI features (e.g. ADC values, T1 relaxation time, enhancement patterns) in relation to early treatment response assessed 4-6 weeks after TACE or 3 months after SIRT using modified RECIST (mRECIST) criteria","4 to 6 weeks after TACE, 3 months after SIRT",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","This prospective, monocentric, observational study evaluates the clinical utility of multiparametric magnetic resonance imaging (mpMRI) in the characterization and management of hepatocellular carcinoma (HCC). The study focuses on how advanced MRI techniques-such as diffusion-weighted imaging (DWI), dynamic contrast-enhanced MRI (DCE-MRI), and quantitative mapping (T1\u002FT2)-can provide functional insights into tumor biology.\n\nConducted at a German university hospital, the study investigates whether mpMRI can improve diagnostic precision and assist in therapeutic decision-making for patients undergoing locoregional treatments like transarterial chemoembolization (TACE) or selective internal radiotherapy (SIRT).\n\nBy integrating multiple MRI biomarkers, the study aims to explore correlations between imaging features and treatment response. Imaging protocols follow current clinical standards, and the study introduces no investigational agents. Radiological evaluations are performed by expert radiologists, and statistical analysis is pre-specified. The study complies with ethical and data protection standards.","Adult patients (≥18 years) with confirmed or suspected HCC who are scheduled for TACE or SIRT as part of routine clinical care at a tertiary academic center. Patients must be eligible for liver MRI and provide informed consent. The population includes treatment-naive as well as previously treated individuals, as long as they meet the inclusion criteria. Recruitment is non-randomized and consecutive.",[20],{"label":21,"type":13,"description":22,"interventionNames":23},"HCC patients undergoing TACE or SIRT","Patients with hepatocellular carcinoma scheduled for TACE or SIRT, undergoing multiparametric MRI at three defined time points.",[24],"Diagnostic Test: Multiparametric MRI",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":13},"DIAGNOSTIC_TEST","Multiparametric MRI","Diagnostic multiparametric liver MRI, performed at three time points: before (≤14 days), 24 hours after, and 4-6 weeks after TACE or 3 months after SIRT.",[21],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Max Masthoff, MD","CONTACT","+492518343018","max.masthoff@ukmuenster.de",{"name":38,"role":34,"phone":39,"phoneExt":13,"email":40},"Philipp Schindler, MD","+492518343015","philipp.schindler@ukmuenster.de",[42],{"facility":43,"status":44,"city":45,"state":13,"zip":13,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Clinic of Radiology, University of Münster","RECRUITING","Münster","Germany","DE",{"type":49,"coordinates":50},"Point",[51,52],7.62571,51.96236,{"lat":52,"lon":51},[55,56,58,59],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},{"name":33,"role":57,"phone":13,"phoneExt":13,"email":13},"PRINCIPAL_INVESTIGATOR",{"name":38,"role":57,"phone":13,"phoneExt":13,"email":13},{"name":60,"role":57,"phone":13,"phoneExt":13,"email":13},"Emily Hoffmann, MD",{"type":57,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Emily Hoffmann","MD","100592879",false,"NCT06999174","Multiparametric MRI for Characterization of Hepatocellular Carcinoma","Multiparametric MRI for Optimized Imaging-based Characterization and Therapy Management of Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed or suspected diagnosis of HCC\n* Scheduled to receive TACE or SIRT as part of standard clinical care\n* Eligibility for liver MRI\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Contraindications to MRI (e.g., pacemakers, ferromagnetic implants, severe claustrophobia)\n* Known allergy or intolerance to gadolinium-based contrast agents\n* Renal insufficiency with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m²\n* Pregnancy or breastfeeding\n* Inability to provide informed consent","ALL","18 Years",{"count":73,"type":74},128,"ESTIMATED","OBSERVATIONAL","This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC). The goal is to evaluate whether advanced MRI parameters can support noninvasive diagnostic assessments and personalized treatment plans for patients with HCC. The study is being conducted at a single university center in Germany and includes adult patients with confirmed or suspected HCC. Participants will undergo standardized multiparametric MRI examinations, and the imaging data will be correlated with clinical, pathological, and therapeutic outcomes. No study-specific interventions or medications will be administered.",[78],"Hepatocellular Carcinoma (HCC)",[28,80,81],"TACE","SIRT","2025-06-28",{"date":84,"type":85},"2025-07-02","ACTUAL",{"date":87,"type":85},"2025-05-01",{"date":89,"type":74},"2028-05-01",{"name":5,"class":6},1]